Artiva Biotherapeutics, Inc. Common Stock (ARTV)vsInsmed Inc (INSM)
ARTV
Artiva Biotherapeutics, Inc. Common Stock
$5.23
-2.61%
HEALTHCARE · Cap: $131.49M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
ARTV leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
ARTV
Avoid26
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARTV
The strongest argument for ARTV centers on Price/Book.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : ARTV
The primary concerns for ARTV are EPS Growth, Market Cap, Profit Margin.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
ARTV profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
INSM is growing revenue faster at 1.5% — sustainability is the question.
ARTV generates stronger free cash flow (-15M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Artiva Biotherapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Artiva Biotherapeutics, Inc. is an innovative biotechnology company focused on developing next-generation cell therapies for cancer. Leveraging a proprietary platform to enhance natural killer (NK) cell therapies, Artiva is advancing an extensive pipeline targeting a variety of hematologic and solid tumors. The company's commitment to scientific excellence and strategic partnerships positions it as a key player in the dynamic field of immuno-oncology. As it moves forward with clinical development of its promising therapeutic candidates, Artiva aims to transform cancer treatment and significantly improve patient outcomes.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?